

Massy – April 25, 2014

Additional private placement of 240K€ : total fundraising increased to 3 650 K€ in 2014

Quantum Genomics, a biopharmaceutical research company developing new treatments in the field of cardiovascular diseases, (Alternext - FR0011648971 - ALQGC), has announced today a capital increase by additional private placements of 240 K€ at the same price per share as the private placement of 3.4 M€ made on April 9th.

The Company has announced on April 9th a round of financing through the private placement of 637,334 new shares priced at 5.35 € each. This round of financing is completed by the additional issue of 44,858 new shares acquired by three investors.

The company recalls that these funds will be used in the short term to finance the clinical development (Phase II) of QGC001, first in class drug candidate for the treatment of hypertension and to support three additional development programs of the Company.

Following this operation, the number of shares of the Company is increased to 4,792,261 shares totally negotiable on Alternext Paris - Euronext.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical research company developing new therapies for unmet medical needs in the field of cardiovascular diseases, including hypertension and heart failure.

Quantum Genomics is in the process of developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.

Quantum Genomics will be listed from 10 April, 2014 on the Alternext market in Paris (ISIN code: FR0011648971 – Ticker symbol: ALQGC).

Contacts

Quantum Genomics

Lionel Ségard
Chief Executive Officer
(+33) 1 60 13 76 80

Quantum Genomics

Marc Karako
Chief Financial Officer – Investor relations
(+33) 1 60 13 76 84
marc.karako@quantum-genomics.com

ACTUS

Jean-Michel Marmillon
Press contact
(+33) 1 53 67 07 80
jmmarmillon@actus.fr

Main characteristics of the capital increase

This fundraising is carried out through a capital increase by issuing ordinary shares, without shareholders' preferential subscription rights or a priority subscription period.

The transaction was conducted through the issuance of 44,858 new shares at a unit price of €5.35 - a total of 239,990.30 € in issuance proceeds. On the basis of a social capital consisting of 4,747,403 shares prior to the transaction, the new total number of shares becomes 4,792,261.

Legal framework

Through the authority granted to shareholders by the Combined Shareholders' General Meeting on 21 November 2013, in its 11th, 12th, 13th and 14th resolutions, the Board of Directors at Quantum Genomics passed a decision, at its meeting held on 1 April, 2014, on the principle of a capital increase without shareholders maintaining their preferential subscription rights within the framework of a private placement, without a public offering, whose procedures are contained in the present release.

Listing of new shares

New shares will be entitled to dividend rights from April 25, 2014, and will be negotiable Alternext Paris – Euronext from April 29th 2014. They will be admitted to trading on the same line as the existing shares (ISIN code: FR0011648971 - ALQGC) and will be fully assimilated following the planned admission for trading date.

Capital breakdown

At the end of the transaction, the distribution of Quantum Genomics social capital is as follows:

▪ Long-standing family offices	46.95%
▪ Managers	17.11%
▪ New private placement investors	10.74%
▪ Floating	25.20%